

Special Issue

Clinical Studies in Gastrointestinal Malignancies

Message from the Guest Editor

Gastrointestinal malignancies pose a major health burden worldwide. They have a relevant mortality and sustained effects on the health and well-being of patients. Treatment is usually multimodal, comprising surgery, radiotherapy, cytotoxic therapy, and targeted therapy and immunotherapy. Tumor stage, molecular tumor characteristics (tumor phenotype), and patient characteristics (host phenotype) are heterogeneous and can change over time, which requires treatments to be increasingly personalized. Moreover, not only do "traditional" outcomes such as tumor response and survival need to be assessed, but also more directly patient-relevant outcomes too, such as functional status, quality of life, and satisfaction with treatment, which can be comprehensively summarized as patient-reported outcome measures and patient-reported experience measures. For this Special Issue of *Cancers*, I invite you to submit up-to-date original research, including meta-analyses reporting on the treatment of gastrointestinal malignancies as well as methodological contributions addressing the design and conduct of studies in the field.

Guest Editor

Prof. Dr. Ulrich Ronellenfitch

Department of Visceral, Vascular and Endocrine Surgery, University Medical Center Halle (Saale), Martin-Luther-University, Halle-Wittenberg, Germany

Deadline for manuscript submissions

closed (1 December 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/225689

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)